Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer

NCT01231802 is registered in ClinicalTrials.gov with Adherex Technologies, Inc. as lead sponsor.

NCT NCT01231802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01231802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer
Lead sponsor
Adherex Technologies, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2011
Completion date
January 31, 2013
Enrollment
140 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer